Shingles and Dementia Risk Study
Part of Brain & nervous system, Heart & circulation, Infections, Mental health clinical trials.
This study looks at whether the virus that causes shingles (herpes zoster) might increase the risk of dementia. Participants with a fresh shingles rash will give blood samples and attend several follow-up visits over one year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new shingles rash that has NOT been treated with antiviral medicine.
- You can return for follow-up visits at 7 days, 1, 3, 6, and 12 months.
- You are willing to have blood drawn.
- You have not had the shingles vaccine in the last 8 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine for healthy adults 40 and older. It aims to see if the vaccine is safe and helps protect against shingles.
This study tests whether the shingles vaccine can reduce the risk of developing dementia in adults 76 and older living in Finland. You would get the vaccine and then researchers will follow your health records for up to several years to see if it protects your brain.
This study is looking at how getting the shingles vaccine affects your quality of life and the overall burden of the disease. Researchers will track your health over time to understand what life is like after vaccination versus not.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Hear when a new Vascular Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.